Platform|API|Archive|Contact

Humanexa SignalsPharmaceutical Intelligence

FDA
EMA
MHRA
PMDA
Health Canada

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Pricing
Access
Commercial
Launch Tracking

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

Regulatory
Clinical
Competitive
Markets
M&A Watch
Strategy
Catalyst Tracker

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Asset / Drug

Rosuvastatin

Drug and asset intelligence for Rosuvastatin with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 2
Catalysts: 1
Stage: Development stage unavailable

Sponsor company

Mankind Pharma →

Recent signals(2)

StrategyAugust 5, 2026

Mankind Pharma's Rosuvastatin Calcium ANDA206603 Receives AP Status

Mankind Pharma's ANDA for Rosuvastatin Calcium has been granted Abbreviated Approval (AP) status by the FDA.

ClinicalJune 28, 2026

Trial Evaluates Dual vs Triple Lipid-Lowering Therapy in Type 2 Diabetes Patients

A clinical trial is underway to compare the efficacy and safety of dual versus triple lipid-lowering therapy in patients with type 2 diabetes and elevated LDL cholesterol.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts(1)

Topline Data

— rosuvastatin

June 28, 2026 · N/A

Indications

No related entities indexed yet.

Therapeutic areas

Cardiovascular →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.